Pressure on Europe’s drug agencies can be eased through public and private means
This article was originally published in Clinica
Executive Summary
The global economic crisis has placed many European industries under financial pressure. To date, however, the pharmaceutical industry has appeared to be remarkably resilient for one simple reason: society demands health. Yet, whilst the industry has maintained a sense of imperviousness, some of the EU member state medicines agencies – many responsible for regulating both pharmaceuticals and medical devices – are beginning to buckle under the pressure of the economic downturn, coupled with the increasing legislative demands that emanate from Brussels.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.